RevolutionLogo.png
Revolution Medicines to Participate in Upcoming Investor Conferences
November 09, 2022 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Origional Logo_Violet_2022.png
AppTech Payments Corp. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 06:00 ET | AppTech Corp.
CARLSBAD, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (AppTech) (NASDAQ: APCX), an innovative Fintech company powering commerce experiences, today announced its Chairman and...
LOGO.png
Nemaura Medical Strengthens Balance Sheet with Further Non-Dilutive Funding
May 23, 2022 06:30 ET | Nemaura Medical, Inc
Loughborough, England, May 23, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on commercializing a daily disposable wearable glucose sensor and...
monopar.jpg
Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020
September 14, 2020 08:30 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at...
Surface Logo New Version-color.png
Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference
September 11, 2020 15:00 ET | Surface Oncology, Inc.
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) --  Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
RevolutionLogo.png
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
33729.jpg
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge
August 24, 2020 08:00 ET | Cancer Genetics, Inc.
Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions RUTHERFORD, NJ and MAPLE GROVE, MN, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the...